Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | May 18 - 19, 2026

May 20, 2026

•

3 min read

Biotech & Pharma Updates | May 18 - 19, 2026

🧬 UCB's Bimzelx (bimekizumab) outperforms Skyrizi in Ph3 head-to-head trial for psoriatic arthritis, Incyte, Edison Scientific partner to deploy Kosmos AI across drug discovery and R&D workflows, Mentari Therapeutics goes public via reverse merger with InMed Pharmaceuticals, raising $290M for migraine pipeline

Christian Cuchapin, +1

Biotech & Pharma Updates | May 17 - 18, 2026

May 19, 2026

•

4 min read

Biotech & Pharma Updates | May 17 - 18, 2026

🧬 Bristol Myers Squibb weighs $1B Houston manufacturing plant that could employ 500 people, Merck & Co.'s (sacituzumab tirumotecan) hits Ph3 mark in endometrial cancer, beating chemotherapy in survival outcomes, Full-Life Technologies raises $150M Series D, advancing radiotherapeutics pipeline and Belgium manufacturing

Christian Cuchapin, +1

Biotech & Pharma Updates | May 13 - 17, 2026

May 18, 2026

•

4 min read

Biotech & Pharma Updates | May 13 - 17, 2026

🧬 Eisai projects $905M in Leqembi revenues for fiscal 2026, driven by subcutaneous auto-injector launch, Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) gains FDA approval for two HER2-positive breast cancer indications following Ph3 data, FDA's CDER, CBER acting directors and chief of staff ousted following Commissioner Makary's departure

Anis Fahandej-Sadi

Biotech & Pharma Updates | May 12 - 13, 2026

May 14, 2026

•

4 min read

Biotech & Pharma Updates | May 12 - 13, 2026

🧬 BeOne Medicines' Beqalzi (sonrotoclax) receives FDA accelerated approval for relapsed or refractory mantle cell lymphoma as first BCL-2 inhibitor, Novo Nordisk's oral semaglutide delivers up to 21.6% weight loss in Ph3 obesity trial, Vetter breaks ground on new Saarlouis production site, investing €500M ($586.75M) to create up to 2,000 jobs

Christian Cuchapin, +1

Biotech & Pharma Updates | May 11 - 12, 2026

May 13, 2026

•

3 min read

Biotech & Pharma Updates | May 11 - 12, 2026

🧬 Isomorphic Labs raises $2.1B Series B to develop AI drug design engine, accelerate pipeline, FDA Commissioner Marty Makary resigns after turbulent tenure marked by White House tensions, Bristol Myers Squibb, Hengrui Pharma build 13-asset oncology and immune disease pipeline in $15.2B deal

Christian Cuchapin, +1

Biotech & Pharma Updates | May 10 - 11, 2026

May 12, 2026

•

3 min read

Biotech & Pharma Updates | May 10 - 11, 2026

🧬 Inhibrx Biosciences' INBRX-106 plus Keytruda (pembrolizumab) doubles response rate in Ph2 head and neck squamous cell carcinoma trial, Daiichi Sankyo targets $14.6B oncology sales by 2030, aiming for global top-five cancer company status, Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy STEM-PD, equity investment undisclosed

Anis Fahandej-Sadi, +1

Biotech & Pharma Updates | May 7 - 10, 2026

May 11, 2026

•

3 min read

Biotech & Pharma Updates | May 7 - 10, 2026

🧬 Quantinuum plans IPO to fund quantum computing platform for drug discovery, Gilead raises Yeztugo 2026 sales target to $1B after strong launch trajectory, argenx's VYVGART (efgartigimod alfa-fcab) receives FDA label expansion for all adult generalized myasthenia gravis serotypes

Christian Cuchapin, +1

Biotech & Pharma Updates | May 6 - 7, 2026

May 8, 2026

•

3 min read

Biotech & Pharma Updates | May 6 - 7, 2026

🧬 Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1B, expanding into U.S. rare neurological drug market, Blackstone invests $250M in Anagram Therapeutics to develop cystic fibrosis EPI therapy, Pierre Fabre, FDA align on Ebvallo BLA resubmission path using updated ALLELE study data

Christian Cuchapin, +1

Biotech & Pharma Updates | May 5 - 6, 2026

May 7, 2026

•

3 min read

Biotech & Pharma Updates | May 5 - 6, 2026

🧬 Eli Lilly pledges additional $4.5B to Indiana campus, expanding genetic medicine and metabolic disease manufacturing, Bayer to acquire Perfuse Therapeutics for up to $2.45B, bolstering eye disease drug pipeline, Novo Nordisk's Wegovy pill hits 1M patients, generates $355M in Q1 sales, beating analyst expectations by 86%

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | May 18 - 19, 2026

Biotech & Pharma Updates | May 17 - 18, 2026

Biotech & Pharma Updates | May 13 - 17, 2026

Biotech & Pharma Updates | May 12 - 13, 2026

Biotech & Pharma Updates | May 11 - 12, 2026

Biotech & Pharma Updates | May 10 - 11, 2026

Biotech & Pharma Updates | May 7 - 10, 2026

Biotech & Pharma Updates | May 6 - 7, 2026

Biotech & Pharma Updates | May 5 - 6, 2026

TLDR Biotech

FAQ

Media Partners